$PDSB
PDS Biotechnology Corp

2024 Q2 Form 10-Q Financial Statement

#000114036124026295 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.157M $3.393M
YoY Change -11.4% -5.18%
% of Gross Profit
Research & Development $4.528M $6.704M
YoY Change -43.44% 14.72%
% of Gross Profit
Depreciation & Amortization $15.12K $4.735K
YoY Change 4.93% 50.08%
% of Gross Profit
Operating Expenses $8.684M $10.10M
YoY Change -31.6% 7.17%
Operating Profit -$8.684M -$10.10M
YoY Change -31.6% 7.17%
Interest Expense -$512.8K $1.175M
YoY Change -151.51% 21.5%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$9.197M -$10.60M
YoY Change -28.93% 9.77%
Income Tax -$869.2K
% Of Pretax Income
Net Earnings -$8.328M -$10.60M
YoY Change -27.8% 9.77%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23 -$0.30
Diluted Earnings Per Share -$0.23 -$0.30
COMMON SHARES
Basic Shares Outstanding 36.68M 36.68M
Diluted Shares Outstanding 36.69M 34.82M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $57.73M $66.63M
YoY Change -4.77% 2.2%
Cash & Equivalents $57.70M $66.60M
Short-Term Investments
Other Short-Term Assets $2.428M $2.051M
YoY Change -10.94% -26.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $60.16M $68.69M
YoY Change -5.03% 1.05%
LONG-TERM ASSETS
Property, Plant & Equipment $152.9K $129.4K
YoY Change 6.5% -12.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $334.5K $320.6K
YoY Change -17.07% -32.54%
TOTAL ASSETS
Total Short-Term Assets $60.16M $68.69M
Total Long-Term Assets $334.5K $320.6K
Total Assets $60.50M $69.01M
YoY Change -5.11% 0.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.252M $6.001M
YoY Change -26.33% 189.61%
Accrued Expenses $1.947M $1.714M
YoY Change -42.33% -7.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $10.48M $7.349M
YoY Change 19549.33% 14002.38%
Total Short-Term Liabilities $15.67M $15.06M
YoY Change 98.31% 264.78%
LONG-TERM LIABILITIES
Long-Term Debt $13.90M $16.76M
YoY Change -40.6% -28.1%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $13.90M $16.76M
YoY Change -40.6% -28.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.67M $15.06M
Total Long-Term Liabilities $13.90M $16.76M
Total Liabilities $29.58M $31.82M
YoY Change -5.53% 15.98%
SHAREHOLDERS EQUITY
Retained Earnings -$163.4M -$155.1M
YoY Change 33.14% 39.46%
Common Stock $12.14K $12.10K
YoY Change 19.13% 19.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.92M $37.18M
YoY Change
Total Liabilities & Shareholders Equity $60.50M $69.01M
YoY Change -5.11% 0.81%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$8.328M -$10.60M
YoY Change -27.8% 9.77%
Depreciation, Depletion And Amortization $15.12K $4.735K
YoY Change 4.93% 50.08%
Cash From Operating Activities -$8.858M -$9.938M
YoY Change 83.99% -24.65%
INVESTING ACTIVITIES
Capital Expenditures $29.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$29.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -13.79K 20.01M
YoY Change -105.75% 338.11%
NET CHANGE
Cash From Operating Activities -8.858M -9.938M
Cash From Investing Activities -29.00K
Cash From Financing Activities -13.79K 20.01M
Net Change In Cash -8.901M 10.07M
YoY Change 94.58% -216.86%
FREE CASH FLOW
Cash From Operating Activities -$8.858M -$9.938M
Capital Expenditures $29.00K
Free Cash Flow -$8.887M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19494473
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4588522
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00033
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36679275
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36679275
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33094521
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33094521
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2080319
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9659918
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
121997
CY2024Q1 us-gaap Depreciation
Depreciation
4735
CY2023Q1 us-gaap Depreciation
Depreciation
3155
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
60257
CY2024Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
9670
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
113758
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-89102
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9938189
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13188636
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20012089
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4567855
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
10073900
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
1174745
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
966845
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
44002030
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2080319
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9659918
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
41010953
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26130947
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1630011
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19494473
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10603477
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
37183045
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10603477
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1630011
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
270236
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
10957
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-443210
CY2024Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
13475
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
20667
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8620781
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56560517
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73820160
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66634417
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65199379
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00033
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-981993
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
852774
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-710581
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6455317
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
531091
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001472091
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6704164
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5843686
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3393463
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3578728
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
10097627
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
9422414
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10097627
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9422414
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
668895
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
729341
CY2024Q1 us-gaap Interest Expense
InterestExpense
1174745
CY2023Q1 us-gaap Interest Expense
InterestExpense
966845
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-505850
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-237504
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10603477
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10603477
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9659918
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9659918
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34815870
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34815870
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30428053
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30428053
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4588522
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
531091
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5780773
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5802140
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66600000
CY2022Q3 pdsb Shelf Registration Statement Available For Future Sale
ShelfRegistrationStatementAvailableForFutureSale
150000000
CY2022Q3 pdsb Placement Shares Available For Future Sale
PlacementSharesAvailableForFutureSale
50000000
CY2022Q3 pdsb Placement Shares Available For Future Sale
PlacementSharesAvailableForFutureSale
50000000
CY2022Q3 pdsb Commission Percentage
CommissionPercentage
0.03
CY2023 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2642269
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16100000
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3428681
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
553293
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19500000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4600000
CY2023Q2 pdsb Proceeds From Sale Of Unused Net Operating Loss Carryforwards
ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
1400000
CY2024Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
66634417
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
56560517
CY2024Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
11200
CY2024Q1 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P40M
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
700000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
700000
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0915
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
89102
CY2024Q1 pdsb Finance Lease Principal And Interest Payments
FinanceLeasePrincipalAndInterestPayments
17463
CY2023Q1 pdsb Finance Lease Principal And Interest Payments
FinanceLeasePrincipalAndInterestPayments
20667
CY2024Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
52387
CY2024Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
69850
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
40108
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
26721
CY2024Q1 pdsb Finance Lease Liability To Be Paid Year Four And Thereafter
FinanceLeaseLiabilityToBePaidYearFourAndThereafter
1
CY2024Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
189067
CY2024Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
23775
CY2024Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
165292
CY2024Q1 pdsb Lessee Finance Lease Number Of Leases
LesseeFinanceLeaseNumberOfLeases
4
CY2024Q1 pdsb Finance Lease Cost
FinanceLeaseCost
251959
CY2024Q1 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.0915
CY2024Q1 pdsb Lessee Finance Lease Monthly Rental Expense
LesseeFinanceLeaseMonthlyRentalExpense
6000
CY2023 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
151490
CY2024Q1 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
457229
CY2023Q4 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
0
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
531294
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
827863
CY2024Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
418449
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1289690
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
306771
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
306771
CY2024Q1 us-gaap Accrued Rent Current
AccruedRentCurrent
368
CY2023Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
368
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1714111
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2424692
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4541
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4202
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0398
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0406
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.22
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.79
CY2024Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
0
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 pdsb Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2024Q1 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
66000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
66000
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
381625
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.6685
CY2024Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P10Y
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
449329
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1994412
CY2024Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1170758
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
961753
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
270236
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
121997
CY2024Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
66488
CY2023Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
94907
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001140361-24-026295-index-headers.html Edgar Link pending
0001140361-24-026295-index.html Edgar Link pending
0001140361-24-026295.txt Edgar Link pending
0001140361-24-026295-xbrl.zip Edgar Link pending
ef20026295_10q.htm Edgar Link pending
ef20026295_ex10-3.htm Edgar Link pending
ef20026295_ex31-1.htm Edgar Link pending
ef20026295_ex31-2.htm Edgar Link pending
ef20026295_ex32-1.htm Edgar Link pending
ef20026295_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image01.jpg Edgar Link pending
image02.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pdsb-20240331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pdsb-20240331_cal.xml Edgar Link unprocessable
pdsb-20240331_def.xml Edgar Link unprocessable
pdsb-20240331_lab.xml Edgar Link unprocessable
pdsb-20240331_pre.xml Edgar Link unprocessable
ef20026295_10q_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending